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Abstract
Since 2002, a workshop entitled “Asthma in animal models” has been held once a year in Hannover,
Germany. It is organized by the Fraunhofer Institute of Toxicology and Experimental Medicine in
collaboration with the collaborative research centre “Sonderforschungsbereich” 587, “Immune
reactions of the lung in infection and allergy” (Hannover Medical School). The aim of these meetings
is an intense scientific exchange between researchers and clinicians coming from academic or
industrial background. Over the years the topics within the extensive field of asthma and COPD
have ranged from methodological aspects to the influence of infections and environmental factors
up to perspectives in the development of new therapeutic strategies.
Editorial
In January 2007, the 6th workshop took place with the
main topics “Interaction of resident lung cells with
inflammation in asthma and COPD”, “Infection and
Asthma” and “New therapeutic Targets against Asthma”.
The workshop was organized by the Fraunhofer Institute
of Toxicology and Experimental Medicine in collabora-
tion with the collaborative research centre “Sonderforsc-
hungsbereich” 587, “Immune reactions of the lung in
infection and allergy” (Hannover Medical School). Some
particularly interesting contributions to the workshop
were selected to be published in this supplement to Jour-
nal of Occupational Medicine and Toxicology since inflam-
matory airway diseases are of major interest for the
research areas covered by the journal [1-9].
Bronchial asthma is a respiratory disease characterized by
chronic inflammation and episodes or attacks of airway
narrowing. The burden from asthma in western societies
has increased over the past decades, but the precise rea-
sons for this increase remain enigmatic so far. In addition,
the exact physiological mechanisms of the development
of asthma, in particular the complex interaction of
chronic inflammation with resident lung cells such as
smooth muscle cells, fibroblasts or neurons are still
unknown.
To understand the disease and subsequently develop new
and effective drugs, the use of predictive animal models is
essential. Since several newly developed highly specific
anti-inflammatory drugs were very effective in murine
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discussion about the adequate animal models emerged.
Bronchial asthma is still a major socioeconomic burden,
that is, 17 million US Americans, with approximately one
third of those being children, were affected by bronchial
asthma in 1996. Also, the economic burden of the disease
is increasing in parallel, from US$6.2 billion in 1990 to an
estimated US$12.7 billion in 1998 [10]. Similar trends are
reported from the Asian region: based on prevalence rates
at present and projected increases, it can be estimated that
the total population of Chinese asthmatic patients will be
around 150 million individuals by the year 2013. This
dramatic numbers includes 38 million children [11].
With regard to the spiraling treatment costs, it is impor-
tant to debate that there should be a substantial realign-
ment of drug development policy in the pharmaceutical
industry and a parallel shift in the licensing policy by
authorities to encourage the development of novel com-
pounds and substance classes that are effective in halting
the progression from acute to chronic forms, when the
disease first manifests in early childhood [12]. These new
agents include both substances that represent improve-
ments of existing drug forms, such as inhaled steroids or
inhaled beta 2 receptor agonists and completely new
classes of drugs. These new classes include agonists and
antagonists of specific extracellular and intracellular
mediators such as neuromediators, cytokines or chemok-
ines as well as modulators of immune responses like toll
like receptor agonists.
It is also important to mention that the pharmacologic
treatment options are not curative. Current and future
approaches should lead to a better long-term control of
chronic airway obstruction. In this respect, it should also
be a major aim to develop novel agents that are as effective
existing drugs but have less side effects and have a better
route of administration [13].
This supplement to JOMT aims to provide a series of
reviews that focus on current knowledge in pathogenesis
and evolving therapeutic options in allergic asthma.
The series starts with an article about the “Role of mast
cells in asthma” [14]. Mast cells are known for long time
to play an important role in the pathophysiology of aller-
gic diseases. Therefore, blocking of mast cell mediators
like histamine is a very commonly used treatment option
in e.g. allergic rhinitis. However, in asthma the role of
mast cells is less well defined and antihistaminic drugs are
less effective. First experiments in mouse models lacking
mast cells could not prove an significant role of mast cells
in the development of allergic asthma [15]. Reuter and
Taube describe in their review that this is due to the
unphysiological sensitization of the animals using adju-
vant. In contrast, in protocols using less potent sensitiza-
tion procedures, the role of mast cells for induction of
allergic airway disease can be proofed. The review gives
detailed insights in the mechanisms of mast cell contribu-
tion by describing the function of the released mediators
like LTB4 and TNF-alpha.
The series continues with an article describing the interac-
tion of allergic airway disease with infections [16]. On the
one hand side lung infections are known to be classical
trigger factors of asthma exacerbations, on the other hand,
exposure to microbial products is known to be protective
against allergic asthma. In addition, Beiswenger and Bals
describe that allergic airway inflammation also inhibits
antimicrobial host defense and renders animals more sus-
ceptible to bacterial infection. The paper elucidates the
complex interaction between allergic inflammation and
microbial infection.
A further focus addresses strategies for the identification
of new therapeutic targets in a chronic asthma model [17].
This review describes the development of improved mod-
els of allergic asthma using repeated allergen aerosol chal-
lenges over several weeks resulting in profound and
sustained allergic airway inflammation, airway hyperre-
sponsiveness and airway remodelling. Wegmann
describes here how he has used this model to test new
compounds like a low molecular weight antagonist of
CCR-3. Special focus is given on the role of T-cells in aller-
gic inflammation and the Th-2 promoting transcription
factor GATA-3 is introduced as an interesting target for
further intervention.
The contribution by Fuchs deals with the function of TLR-
2 agonists in allergic lung inflammation [18]. In this
paper, the biology of TLR-2 is described and the function
of this receptor in innate and adaptive immune response
of the lung is highlighted. TLR-2 is of particular interest
since genetic variation in TLR2 is a major determinant of
the susceptibility to asthma and allergies in children [19].
In animal models the immune modulatory capacity of
TLR-2 agonists like MALP-2 is demonstrated. However,
for effective treatment of experimental asthma the addi-
tion of IFN-gamma is augmenting treatment success.
The last two contributions of the supplement provide an
analysis of novel mechanisms of inflammation [20] and
scientiometric data [21].
Taken together, this supplement gives insights in the
actual discussion regarding animal models of asthma and
shows some examples of how they are used to elucidate
the pathophysiology of the disease and develop new ther-
apeutics against asthma.Page 2 of 3
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